10-Q: Senseonics Q3 Revenue Soars Amid Commercial Shift, Going Concern Doubt Persists

Senseonics Holdings, Inc. reported a significant revenue increase in Q3 2025, driven by U.S. sales and 365-day product demand, even as management acknowledges substantial doubt about its ability to continue as a going concern.

Summary

• Total revenue for the three months ended September 30, 2025, increased by 90% to $8.1 million, up from $4.3 million in the same period of 2024.
• Total revenue for the nine months ended September 30, 2025, increased by 48% to $21.0 million, compared to $14.2 million in the same period of 2024.
• Gross profit for Q3 2025 was $3.5 million, representing a 42.8% gross margin, a significant improvement from a gross loss of ($4.1) million (-95.0% margin) in Q3 2024.
• Net loss for Q3 2025 improved to ($19.5) million from ($24.0) million in Q3 2024.
• Net loss for the nine months ended September 30, 2025, improved to ($48.3) million from ($63.1) million in the same period of 2024.
• Unrestricted cash, cash equivalents, and marketable securities totaled $111.0 million as of September 30, 2025.
• The company signed a memorandum of understanding (MOU) with Ascensia Diabetes Care Holdings AG to transfer commercial operations for Eversense back to Senseonics, with the transition expected to begin January 1, 2026.
• A 1-for-20 reverse stock split was effected on October 17, 2025, with stock trading on a post-split basis starting October 20, 2025.
• Management has determined that substantial doubt exists regarding the company's ability to continue as a going concern for the next twelve months.
• Research and development expenses decreased by $2.7 million in Q3 2025 due to the completion of Eversense 365 system clinical trials and a reduction in headcount.
• Selling, general and administrative expenses increased by $7.0 million in Q3 2025, primarily due to investments in direct-to-consumer marketing and higher sales commissions.

Sentiment

Score: 4

Explanation: While revenue growth and gross margin improvement are positive, the explicit "going concern" warning, continued substantial net losses, and the significant operational and financial risks associated with taking over commercialization from Ascensia temper optimism. The capital raises provide some runway but the underlying profitability challenge remains.

Positives

• Total revenue for Q3 2025 increased by 90% to $8.1 million, up from $4.3 million in Q3 2024, driven by U.S. sales growth.
• Gross profit for Q3 2025 was $3.5 million (42.8% margin), a significant improvement from a gross loss of ($4.1) million (-95.0% margin) in Q3 2024, partly due to favorable margins on 365-day product sales and one-time charges in the prior year.
• Net loss improved to ($19.5) million in Q3 2025 from ($24.0) million in Q3 2024, and to ($48.3) million for the nine months ended September 30, 2025, from ($63.1) million in the prior year period.
• Successful FDA 510(k) clearance for Eversense 365 on September 17, 2024, and subsequent commercialization in the United States.
• Expanded Medicare coverage for Eversense E3 in February 2024 to include all people with diabetes using insulin and non-insulin users with a history of problematic hypoglycemia.
• CMS updated payment amounts in April 2025 for the longer duration Eversense 365 for eligible Medicare beneficiaries.
• Successfully raised approximately $52.1 million net from a Public Offering and $20.1 million net from a Private Placement with Abbott Laboratories in May 2025.
• The Amended Loan and Security Agreement increased the total loan commitment from $50.0 million to $100.0 million, providing access to an additional $65.0 million in undrawn tranches.
• First-in-human testing for the next-generation Gemini product, a fully implantable self-powering system, began in July 2024.
• Entered into a collaboration agreement with Sequel Med Tech in April 2025 to integrate technologies for the first automated insulin delivery system with a once-yearly CGM.

Negatives

• Continued significant net losses: ($19.5) million for Q3 2025 and ($48.3) million for the nine months ended September 30, 2025.
• Accumulated deficit of $996.2 million as of September 30, 2025.
• Management has determined that substantial doubt exists regarding the company's ability to continue as a going concern for the next twelve months.
• Selling, general and administrative expenses increased by $7.0 million in Q3 2025, primarily due to increased promotional expenses and sales commissions.
• Significant reliance on Ascensia for revenue (48% in Q3 2025, 56% for nine months ended September 30, 2025), with the commercialization agreement now transitioning back to the company.
• The transition of commercial operations from Ascensia back to Senseonics will require significant increases in operating expenses and the development of internal sales, marketing, and distribution capabilities, with uncertain total costs and liabilities.
• Potential operational challenges and inefficiencies are expected during the transition of personnel and commercial responsibilities from Ascensia.
• The 1-for-20 reverse stock split may decrease the liquidity of common stock and magnify any decrease in overall market capitalization.
• An ongoing patent infringement lawsuit by Cellspin Soft, Inc. against the company and Ascensia Diabetes Care Holdings AG poses a legal risk, with proceedings currently stayed due to a USPTO review.

Risks

• Substantial doubt exists regarding the company's ability to continue as a going concern for the next twelve months, requiring additional liquidity.
• The transition of commercial responsibility for Eversense from Ascensia back to Senseonics is subject to final definitive agreement, uncertain government approval processes in Europe, and potential for less favorable terms or higher costs.
• Resuming commercial responsibility for Eversense requires developing internal sales, marketing, and distribution capabilities, recruiting and training personnel, and may lead to increased operating expenses that revenue increases may not cover.
• Limited operating history as a commercial-stage company means facing difficulties common to early commercialization in competitive and rapidly evolving markets, including obtaining regulatory approvals and expanding sales infrastructure.
• Failure to successfully expand commercialization of Eversense in the United States and Europe, dependent on market acceptance, reimbursement, and education, would harm the business.
• Ongoing responsibilities under U.S. and EU regulations, periodic inspections, and potential enforcement actions (bans, suspensions, recalls, penalties) if non-compliant or products are deemed ineffective or pose an unreasonable health risk.
• The collaboration with Sequel Med Tech for an automated insulin delivery system may incur unexpected costs, distract from other priorities, face technological challenges, intellectual property disputes, or fail to yield anticipated financial benefits.
• Reliance on a global supply chain exposes the company to international trade policies, including tariffs, sanctions, and trade barriers, which could increase costs, reduce profitability, and delay development timelines.
• The company will need to generate significant sales to achieve profitability, and there is no assurance it can sustain or increase profitability on a quarterly or annual basis.
• The 1-for-20 reverse stock split may not result in a sustained increase in stock price, could decrease liquidity, and magnify any decrease in market capitalization.
• Future success depends on retaining key executives and attracting/retaining qualified scientific, clinical, and marketing personnel, including a sales force, in a competitive environment.
• Significant growth in employees and operations (sales, marketing, R&D) may be difficult to manage effectively with limited financial resources and management experience, potentially disrupting operations.
• An ongoing patent infringement lawsuit by Cellspin Soft, Inc. could result in material costs and occupy management resources, despite the current stay.

Future Outlook

The company expects to incur additional losses in the near future and its ability to grow revenues and achieve profitability depends on the successful commercialization and adoption of its Eversense System, future product development, and regulatory approvals. The transition of commercial activities back to the company and continued development of the Gemini and Freedom products will require significant working capital through 2025 and beyond. The company will require additional liquidity to continue operations over the next twelve months and is evaluating strategies to obtain the required additional funding. It anticipates increasing investment in direct-to-consumer (DTC) marketing, expecting it to correlate with higher awareness and adoption of Eversense. An IDE submission for the Gemini product is anticipated by the end of 2025, and Eversense 365 is planned for launch in European markets during the first half of 2026, pending CE Mark approval. Following the termination of the Ascensia Commercialization Agreement, revenues and results of operations will not be directly comparable to historical periods.

Management Comments

• "Based on our current operating plan including expected capital investments required to assume commercialization and distribution responsibilities, existing unrestricted cash and cash equivalents, minimum cash requirements and satisfaction of performance milestones to comply with debt covenants under its Amended Loan and Security Agreement as discussed in Note 12, the Company has determined that substantial doubt exists regarding its ability to continue as a going concern."
• "The Company will require additional liquidity to continue its operations over the next twelve months and we are currently evaluating strategies to obtain the required additional funding for future operations."
• "We anticipate that our principal uses of cash in the future will be primarily to fund our operations, working capital needs, capital expenditures and other strategic initiatives."
• "We are determined to increase investment in supporting DTC spending, which we believe correlates with higher awareness and adoption of Eversense."
• "Once we build out and establish the Eon Care network, we expect established CPT codes associated with Eversense insertions to enable a self-sustaining economic model for this initiative in the future."
• "We are actively working towards the integration of the companies products [with Sequel Med Tech] to be completed in the fourth quarter of 2025 and available to consumers shortly thereafter."

Industry Context

Senseonics operates in the highly competitive and rapidly evolving continuous glucose monitoring (CGM) market within diabetes management. Its implantable CGM systems, Eversense E3 and Eversense 365, differentiate themselves with significantly longer wear times compared to most non-implantable systems. The company's development of next-generation products like Gemini (a 2-in-1 CGM and flash glucose monitor) and Freedom (Bluetooth-enabled sensor) reflects the industry's push towards more convenient and integrated solutions. Strategic collaborations, such as with Sequel Med Tech for an automated insulin delivery system, align with the broader trend of integrated diabetes care. Regulatory achievements like FDA 510(k) clearance for Eversense 365 and expanded Medicare coverage are crucial for market access and adoption, indicating a growing acceptance of advanced diabetes technologies. The decision to take back commercial operations from Ascensia highlights a strategic shift to gain greater control over market penetration and distribution in a specialized medical device sector.

Comparison to Industry Standards

• Eversense E3 (180-day) and Eversense 365 (365-day) offer significantly longer wear times than typical non-implantable CGM systems (7-15 days) from competitors like Dexcom (G6, G7) and Abbott (Freestyle Libre), providing a key differentiation in patient convenience.
• The Mean Absolute Relative Difference (MARD) of 8.5% for Eversense E3 is competitive within the CGM market, comparable to or better than some leading non-implantable systems (e.g., Dexcom G6 at 9.0% for adults, Freestyle Libre 2 at 9.3%).
• The FDA's De Novo pathway authorization for Eversense 365 as an iCGM establishes special controls, positioning it as a predicate device for future 510(k) submissions, a significant regulatory milestone that can streamline future product introductions.
• The collaboration with Sequel Med Tech aims to create the first automated insulin delivery system with a once-yearly CGM, positioning Senseonics at the forefront of integrated diabetes management solutions, an area where companies like Medtronic, Tandem Diabetes Care, and Insulet are also actively innovating.
• Expanded Medicare coverage for Eversense E3 and updated payment amounts for Eversense 365 reflect increasing recognition and reimbursement for implantable CGM technology, aligning with broader industry efforts to expand patient access to advanced diabetes care.

Corporate Governance

Legal Proceedings

• Cellspin Soft, Inc. vs. Senseonics Holdings, Inc., and Ascensia Diabetes Care Holdings AG (Case No. 2:24-cv 263): A patent infringement lawsuit filed in the Eastern District of Texas in May 2024, alleging infringement of three patents. The validity of these patents is being challenged in Inter Partes Review (IPR) proceedings at the U.S. Patent and Trademark Office (USPTO) by TikTok Inc. The Patent Trial and Appeal Board instituted a review on September 30, 2024. The court stayed the proceedings on February 5, 2025, pending IPR resolution. On June 5, 2025, the Acting Director of the USPTO ordered a sua sponte review of whether the TikTok IPR could proceed based on TikTok's Chinese ownership status, staying all IPR proceedings. The company intends to vigorously defend the lawsuit if asserted claims survive the IPR proceedings.

Related Party Transactions

• Ascensia Diabetes Care Holdings AG (Ascensia): A related party through its parent company, PHC Holdings Corporation (PHC), which has a noncontrolling ownership interest and Board representation. Sales to Ascensia accounted for 48% of total revenue in Q3 2025 and 56% for the nine months ended September 30, 2025. Ascensia earned commissions of $2.1 million on consignment sales for the nine months ended September 30, 2025. The amount due from Ascensia was $2.7 million as of September 30, 2025, and the amount due to Ascensia was $3.7 million. The company purchased less than $0.1 million in medical supplies from Ascensia for clinical trials. A memorandum of understanding (MOU) was signed on September 3, 2025, for the transfer of commercial operations back to Senseonics, with the termination of the existing Commercialization Agreement contemplated and transition expected to begin January 1, 2026.
• PHC Holdings Corporation (PHC): Parent company of Ascensia, with a noncontrolling ownership interest and Board representation. The company issued a Purchase Warrant to PHC in March 2023 to purchase 771,288 shares of common stock for $15.0 million. In March 2023, the company entered into an exchange agreement with PHC, exchanging $35.0 million aggregate principal amount of convertible notes for a warrant (PHC Exchange Warrant) to purchase 3,426,266 shares of common stock.

Stakeholder Impact

• Shareholders: Experience a mix of positive (revenue growth, improved gross margin, capital raises, new product development) and negative (going concern warning, continued net losses, risks of commercial transition, patent infringement lawsuit, potential liquidity impact from reverse stock split) impacts.
• Employees: Affected by past company restructuring and R&D headcount reduction. Future success depends on recruiting and retaining qualified personnel, especially for sales and marketing post-Ascensia transition, with potential for disruption during this period.
• Customers (Diabetes Patients & Healthcare Providers): Potential for improved access to advanced, longer-duration glucose monitoring solutions through Eversense systems, new products (Gemini, Freedom), and the Sequel collaboration. Expanded Medicare coverage and Eon Care initiatives aim to enhance access. However, the commercial transition from Ascensia could lead to temporary disruptions in supply or support.
• Suppliers/Creditors: Reliance on third-party manufacturers and a global supply chain. The expanded loan facility provides increased debt capacity, but the going concern warning could raise concerns regarding future payments and compliance with debt covenants.
• Regulatory Authorities: Ongoing engagement with U.S. and EU regulatory bodies for product approvals and compliance. The patent infringement lawsuit involves the USPTO.

Next Steps

• Negotiate definitive agreements with Ascensia for the transfer of commercial operations, with the transition expected to begin January 1, 2026.
• Cooperate with Ascensia through the transition period to ensure continuity of supply, customer support, and patient access.
• Develop internal sales, marketing, and distribution capabilities to resume commercial responsibility for Eversense.
• Recruit, hire, and train additional sales, marketing, and supportive personnel.
• Increase investment in direct-to-consumer (DTC) marketing spending.
• Build out and establish the Eon Care network to support patient access to Eversense systems.
• Continue development of the Gemini product, with an IDE submission anticipated by the end of 2025.
• Continue development of the Freedom product.
• Launch Eversense 365 in European markets during the first half of 2026, pending CE Mark approval.
• Evaluate strategies to obtain additional funding for future operations beyond the next twelve months.
• Monitor capital structure and market conditions for potential public or private debt and equity financings.
• Vigorously defend the patent infringement lawsuit by Cellspin Soft, Inc. if the IPR proceedings do not resolve it.
• Actively monitor international trade policies, tariffs, and trade restrictions.

Key Dates

Recommendation

While Senseonics demonstrates strong revenue growth and improved gross margins, the explicit "substantial doubt about its ability to continue as a going concern" and the significant operational risks associated with taking over commercialization from Ascensia create substantial uncertainty. The recent capital raises provide some liquidity, but the path to sustained profitability remains unclear. Investors should hold to monitor the execution of the commercial transition, progress on new product development (Gemini, Freedom), and the company's ability to secure additional funding and achieve profitability. The stock is speculative, and the going concern risk is a major red flag, but the product innovation and market growth suggest potential if these risks are managed effectively.

Keywords

Continuous Glucose Monitoring, CGM, Diabetes Management, Eversense, Implantable Sensor, Medical Technology, Financial Results, Commercialization, Reverse Stock Split, Going Concern, Capital Raise, FDA Approval, Medicare Coverage, Sequel Med Tech, Patent Infringement